Nanotechnology in Global Medicine and Human Biosecurity: Private Interests,Policy Dilemmas,and the Calibration of Public Health Law

Faunce T. A. , Nanotechnology in Medicine and Biosecurity: Dilemmas for Bioethics, Public Health Law and International Human Rights, lecture presented at Johns Hopkins Bloomberg School of Public Health, Baltimore, Tuesday, April 17, 2007.

U.S. Food and Drug Administration, Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force , July 25, 2007, available at <http://www.fda.gov/nano-technology/taskforce/report2007.html> (last visited September 15, 2007).

United Nations Educational, Scientific and Cultural Organization, Universal Declaration on Bioethics and Human Rights, available at <http://portal.unesco.org/en/ev.php-URL_ID=31058&URL_DO=DO_TOPIC&URL_SECTION=201.html> (last visited September 14, 2007).

United Nations, Office for the High Commissioner of Human Rights, available at <http://www.unhchr.ch/udhr/> (last visited September 15, 2007); United Nations, Universal Declaration of Human Rights , General Assembly Resolution 217A (III), U.N. Doc. A/810 (1948) 71, adopted December 10, 1948.

United Nations, International Covenant on Civil and Political Rights , General Assembly Resolution 2200A (XXI), U.N. GAOR Supp. (No. 16) at 52, U.N. Doc. A/6316 (1966), 999 U.N.T.S. 171, adopted December 16, 1966, entered into force March 23, 1976, reprinted in International Legal Materials 6 (1967): 368.

United Nations, International Covenant on Economic, Cultural and Social Rights , General Assembly Resolution 2200A (XXI), U.N. Doc. A/6316 (1966), 993 U.N.T.S. 3, adopted December 16, 1966, entered into force January 3, 1976, reprinted in International Legal Materials 6 (1966): 360.

Rawls A. , Theory of Justice (Oxford: Oxford University Press, 1971).

Brower V. , “Is Nanotechnology Ready for Primetime?” Journal of the National Cancer Institute 98, no. 1 (2006): 9–11.

U.S. Food and Drug Administration, Nanotechnology: A Report of the U.S. Food and Drug Administration Nanotechnology Task Force , July 25, 2007, available at <http://www.fda.gov/nano-technology/taskforce/report2007.html> (last visited September 15, 2007) [hereinafter cited as FDA]; The Royal Society, Nanoscience and Nanotechnologies: Opportunities and Uncertainties, R.S. Policy Document 19/04, Cardiff, 2004.

Sone J. Fujita J. Ochiai Y. , “Nanofabrication toward Sub− 10 nm and its Application to Novel Nanodevices,” Nanotechnology 10 (1999): 135–41.

Wagner V. Dullart A. Bock A.-K. Zweck A. , “The Emerging Nanomedicine Landscape,” Nature Biotechnology 24, no. 10 (2006): 1211–18.

Ghadiri M. R. , “Antibacterial Agents Based on the Cyclic D, L Peptide Architecture,” Nature 412 (2001): 451–55.

Bottini M. Bruckner S. Nika K. , “Multi-Walled Carbon Nanotubules Induce T Lymphocyte Apoptosis,” Toxicology Letters 160 (2006): 121–26.

Leary S. P. Liu C. Y. Yu C. , “Toward the Emergence of Nanoneurosurgery: Part I-Progress in Nanoscience, Nanotechnology and the Comprehension of Events in the Mesoscale Realm,” Neurosurgery 57, no. 4 (2005): 606–33.

Kong D. F. Goldschmidt-Clermont P. J. , “Tiny Solutions for Giant Cardiac Problems,” Trends in Cardiovascular Medicine 15, no. 6 (2005): 207–11.

Hulstein J. J. , “A Novel Nanobody that Detects the Gain-of-Function Phenotype of von Willebrand Factor in ADAMTS13 Deficiency and von Willebrand Disease Type 2B,” Blood 106, no. 9 (2005): 3035–42.

Prestidge C. A. , Nanoscience Facilitating the Development of Novel Pharmaceutical Delivery Systems , abstract of paper presented at the Australian Research Council Nanotechnology Network International Conference on Nanoscience and Naotechnology, Brisbane Convention Centre, July 3–7, 2006.

See FDA, supra note 9.

Ontario Health Technology Advisory Committee, Report on Nanotechnology, available at <http://www.health.gov.on.ca/english/providers/program/ohtac/tech/techlist_2006.html> (last visited September 26, 2007).

See supra note 9.

Alberts B. , “Modeling Attacks on the Food Supply,” Proceedings of the National Academy of Sciences 102, no. 28 (2005): 9737–38.

Wein L. M. Liu Y. , “Analyzing a Bioterror Attack on the Food Supply: The Case of Botulinum Toxin in Milk,” Proceedings of the National Academy of Sciences 102, no. 28 (2005): 9984–89.

Nuzzo J. B. , “The Biological Threat to U.S. Water Supplies: Toward a National Water Security Policy,” Biosecurity and Bioterrorism 4, no. 2 (2006): 147–59.

Jackson R. J. Ramsay A. J. Christensen C. D. Beaton S. Hall D. F. Ramshaw I. A. , “Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox,” Journal of Virology 75 (2001): 1205–10.

Taubenberger J. K. Reid A. H. Lourens R. M. Wang R. Jin G. Fanning T. G. , “Characterization of the 1918 Influenza Virus Polymerase Genes,” Nature 437 (2005): 889–93; Tumpey T. M. , “Characterization of the Reconstructed 1918 Spanish Influenza Pandemic Virus,” Science 310 (2005): 77–80.

Hamilton D. S. Smith B. T. , “Atlantic Storm,” EMBO Report 7 (2006): 4–9.

Wood S. Jones R. Geldart A. , “Social and Economic Challenges of Nanotechnology,” Economic and Social Research Council, Swindon, U.K., 2003.

See generally Kahneman D. , “Maps of Bounded Rationality: Psychology for Behavioral Economics,” American Economic Review 93 (2003): 1449–75; Faunce T. A. , Who Owns Our Health? Medical Professionalism, Law and Leadership Beyond the Age of the Market State (Sydney: UNSW Press/Johns Hopkins University Press, 2007).

Pretty's Case [2002] 1 FLR 268, Case of Pretty v. U.K. (application no. 2346/02).

Minister of Health v. Treatment Action Campaign (2002) Case CCT 8/02.

Institute of Occupational Medicine for the Health and Safety Executive, Nanoparticles: An Occupational Hygiene Review , 2004, available at <http://www.hse.gov.uk> (last visited September 15, 2007).

Department of Employment and Workplace Relations (DEWR), Australian Government, Submission to Senate Inquiry into Workplace Exposure to Toxic Dusts and Nanoparticles , Canberra, August 2005.

See supra note 9.

Flinders Consulting Pty Ltd., A Review of the Potential Occupational Health and Safety Implications of Nanotechnology , Australian Safety and Compensation Council, 2006, available at <http://www.ascc.gov.au/ascc/AboutUs/Publications/ResearchReports/AReviewofthePotentialOccupation-alHealthandSafetyImplicationsofNanotechnology.htm> (last visited September 14, 2007).

Faunce T. A. , “Nanotherapeutics: New Challenges for Safety and Cost-Effectiveness Regulation in Australia,” Medical Journal of Australia 186, no. 4 (2007): 189–91.

See FDA, supra note 2.

Ray W. A. Stein C. M. , “Reform of Drug Regulation: Beyond an Independent Drug-Safety Board,” New England Journal of Medicine 354, no. 2 (2006): 194–201.

Baluch A. S. , “Angstrom Medica: Securing FDA Approval and Commercializing a Nanomedical Device,” Nanotechnology Law and Business 2 (2005): 168–73.

Till M. C. Simkin M. M. Maebius S. , “Nanotech Meets the FDA: A Success Story about the First Nanoparticlate Drugs Approved by the FDA,” Nanotechnology Law and Business 2 (2005): 163–67.

See Faunce , supra note 36.

The United Nations Conference on Environment and Development, Rio Declaration on Environment and Development, United Nations Environment Programme, 1992.

See The Royal Society, supra note 9.

Owens J. , “2006 Drug Approvals: Finding the Niche,” Nature Reviews Drug Discovery 6 (2007): 99–101.

Vastg B. , “The Policy Outlook from the Hill,” Nature Biotechnology 25, no. 1 (2007): 13–16.

See The Royal Society, supra note 9.

European Science Foundation, Nanomedicine: An ESF-European Medical Research Councils (EMRC) Forward Look Report, European Science Foundation, Strasbourg, 2005.

Moran N. , “Danish Biotech Outperforms its European Counterparts,” Nature Biotechnology 24 (2006): 1460–61.

Australian Academy of Science, Nanotechnology Benchmarking Project, available at <http://www.science.org.au/policy/nano-exec.htm> (last visited September 14, 2007).

Australian Government, “Australian Nanotechnology: Capability and Commercial Potential,” 2nd ed., Canberra, 2005.

See Hulstein , supra note 16.

Institute for Soldier Nanotechnologies, Enhancing Soldier Survivability , MIT Web site, available at <http://web.mit.edu/ISN/> (last visited June 1, 2007).

Roco M. C. , “National Nanotechnology Investment in the FY 2003 Budget Request by the President,” National Nanotechnology Web site, available at <http://www.nano.gov/2003budget.html> (last visited September 14, 2007).

Reynolds J. G. Hart B. R. , “Nanomaterials and Their Application to Defense and Homeland Security,” JOM 56, no. 1 (2004): 36–39.

Faunce T. A. Lexchin J. , “‘Linkage’ Pharmaceutical Evergreening in Canada and Australia,” Australian and New Zealand Journal of Health Policy 4, no. 1 (2007): 8 (online publication); Faunce T. A. , “Reference Pricing for Pharmaceuticals: Is the Australia-United States Free Trade Agreement Affecting Australia's Pharmaceutical Benefits Scheme?” Medical Journal of Australia 187, no. 4 (2007): 1–3.

Lopez-Casasnovas G. Puig-Junoy J. , “Review of the Literature on Reference Pricing” in Lopez-Casasnovas G. Jonsson B. , eds., Reference Pricing and Pharmaceutical Policy (Barcelona: Springer-Verlag, 2001): At 13; Productivity Commission, International Pharmaceutical Price Differences: Research Report , Ausinfo, Canberra, 2001; Commonwealth of Australia, National Medicines Policy , Australian Government Web site, available at <http://www.health.gov.au/internet/wcms/publishing.nsf/Content/nmp-objectives-policy.htm> (last visited September 14, 2007); Office of the U.S. Trade Representative, Korea-United States Free Trade Agreement , at Chapter Five: Pharmaceutical and Medical Devices, available at <http://www.ustr.gov/Trade_Agreements/Bilateral/Republic_of_Korea_FTA/Draft_Text/Section_Index.html> (last visited September 14, 2007); von Weizsäcker E. U. Young O. R. Finger M. , eds., Limits to Privatisation: How to Avoid Too Much of a Good Thing? (London: Earthscan Publications, 2006).

Id. (Lopez-Cassanovas and Puig-Junoy).

Judgment No. T-505, August 28, 1992, Columbian Constitutional Court in (1992) 21 Revista Mensual Jurisprudencia Doctrina 1101, Amparo Action against the Ministry of Health, Supreme Court of Justice, Republic of Venezuela, June 9, 1998.

See Faunce , supra note 28.

See generally Kahneman D. , “Maps of Bounded Rationality: Psychology for Behavioral Economics,” American Economic Review 93 (2003): 1449–75.

Faunce T. A. , “Toward a Treaty on Safety and Cost-Effectiveness of Pharmaceuticals and Medical Devices: Enhancing an Endangered Global Public Good,” Globalization and Health 2 (2006): 5–15.

Thomas J. , “Nanotechnology and Surveillance: Little Brother Is Watching You,” Chain Reaction 97 (2006): 29–33.

Monahan T. , ed., Surveillance and Security: Technological Politics and Power in Everyday Life (London: Routledge, 2006).

United Nations, States Parties to Biological Weapons Convention Conclude Meeting After Discussing Scientific Codes of Conduct, Press Release DC05044E, New York, December 9, 2005.

Atlas R. , “Statement on Scientific Publication and Security,” Science 299 (2003): 1149–52.

Kaul I. , “Financing Global Public Goods: Challenges,” in Weizsäcker , eds., supra note 57, at 311.

Beauchamp T. L. , “Principlism and its Alleged Competitors,” Kennedy Institute of Ethics Journal 5, no. 3 (1995): 181–92.

Faunce T. A. , “Developing and Teaching the Virtue-Ethics Foundations of Healthcare Whistle Blowing,” Monash Bioethics Review 23, no. 4 (2004): 41–55.

U.S. National Academy of Sciences, Biotechnology Research in an Age of Terrorism (Washington, D.C.: National Academies Press, 2004).